Actively Recruiting

Age: 18Years - 70Years
All Genders
ID07054229

Efficacy and Prognosis of Microwave Ablation Treatment for Papillary Thyroid Microcarcinoma Assessed by Contrast-Enhanced Ultrasound Combined With Genetic and Molecular Diagnostics: A Prospective Observational Study

Led by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Updated on 2025-07-08

480

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the effectiveness and prognosis of microwave ablation therapy for treating papillary thyroid microcarcinoma (PTMC), a common type of thyroid cancer with a diameter of 10 mm or less. PTMC is typically low-risk with mild behavior and good survival rates, but surgery, the usual treatment, can affect thyroid function and quality of life. This study also examines the use of contrast-enhanced ultrasound combined with genetic and molecular diagnostics to better assess treatment outcomes and assist clinical decisions. The study observes patients aged 18 to 70 with low-risk PTMC who have a single small lesion without metastasis or extrathyroidal extension. Participants undergo fine-needle aspiration and a panel test of 88 genes related to thyroid cancer before choosing either microwave ablation therapy or surgical resection. Contrast-enhanced ultrasound uses safe contrast agents like SonoVue to provide clearer imaging, helping to evaluate the treatment's effectiveness over time. Participants will be monitored at multiple intervals after treatment, including 1, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54, and 60 months post-operation. During these visits, ultrasound imaging and genetic assessments will be performed to track treatment response and prognosis. The study aims to gather detailed data on the safety and outcomes of microwave ablation compared to surgery, supporting improved treatment choices for patients with PTMC.

CONDITIONS

Brief Title

Efficacy and Prognosis of Microwave Ablation Treatment for Papillary Thyroid Microcarcinoma Assessed by Contrast-Enhanced Ultrasound Combined With Genetic and Molecular Diagnostics: A Prospective Observational Study

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Aged 18-70 years
  • Diagnosed with low-risk papillary thyroid microcarcinoma receiving initial treatment
  • Single lesion with maximum diameter 641 cm
  • No cervical lymph node metastasis
  • No distant metastasis
  • No extrathyroidal extension
  • No family history of thyroid cancer
  • No history of head and neck radiation during childhood
  • Underwent fine-needle aspiration cytology of thyroid nodules
  • Completed 88-gene panel testing for thyroid cancer
  • Voluntarily choose microwave ablation therapy or surgical resection
Not Eligible

You will not qualify if you...

  • Tumor located in the isthmus of the thyroid
  • Pathological high-risk subtypes (tall cell, columnar cell, diffuse sclerosing, solid/insular, oncocytic)
  • Progressive enlargement of cancer lesion by more than 3 mm within 6 months
  • Pregnant or lactating women
  • Severe coagulation disorders
  • Contralateral vocal cord dysfunction
  • Contraindications to ultrasound contrast agents
  • Other conditions deemed ineligible by investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Up to 2 weeks

Participants undergo fine-needle aspiration cytology and 88-gene panel testing for thyroid cancer to confirm diagnosis and assess genetic risk factors.

1 to 2 visits (in-person)

Treatment

Duration - Single treatment session

Participants receive microwave ablation therapy for papillary thyroid microcarcinoma as their selected initial treatment.

1 treatment visit (in-person)

Monitoring

Duration - Up to 60 months post-treatment

Participants are monitored with contrast-enhanced ultrasound and clinical assessments to evaluate treatment efficacy and detect any recurrence or metastasis.

Visits at 1, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54, and 60 months post-treatment

Trial Site Locations

Total: 1 location

1

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Guangzhou, Guangdong, China, 510120

Actively Recruiting

Loading map...

Research Team

O

Ou, Dr.

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

Active Surveillance of Papillary Thyroid Microcarcinoma

Papillary Thyroid Microcarcinoma

Actively Recruiting

1 location

Thermal Ablation Combined With Low-dose Donafinib for Early ...

Hepatocellular Carcinoma

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here